Benevolent AI (Benevolent AI) Capital Expenditure : $-1.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Benevolent AI's cash flow for capital expenditures for the three months ended in Dec. 2023 was $-0.52 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40 Mil.

Benevolent AI Capital Expenditure Historical Data

The historical data trend for Benevolent AI's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Capital Expenditure Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-0.97

-1.89

-1.23

-1.41

-1.40

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capital Expenditure	Get a 7-Day Free Trial				-	-0.79	-0.63	-0.88	-0.52

Benevolent AI Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40 Mil.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.